[From breast surgery to HER2 status: the role of the surgeon in molecular-targeted therapy].
Clinical oncology has entered a new era these days: individualized molecular diagnostics and targeted therapy is becoming increasingly accepted. Implementation of these new possibilities has changed our view and the strategy of therapeutical decision-making. Transformed clinical praxis provides ever developing outcome. One of the best examples is trastuzumab, the first targeted therapy used for the treatment of HER2 positive tumors. Trastuzumab combined with the conventional therapies in the adjuvant setting dramatically improves the chance of cure. Surgeons have a dual role in the treatment of the patients: first, they remove the tumor which is the basis of curative treatment, and second, by providing tissue sample of appropriate quality for detailed pathological examinations, they promote correct and up-to-date oncological treatment. The contribution of surgeons is crucial for individualized postoperative therapy eventuating superior outcome.